Olympus launches comprehensive global educational platform for healthcare professionals

Olympus Corporation (Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced the launch of a new comprehensive educational platform designed to provide healthcare professionals (HCPs) all over the world with learning opportunities and training to put their skills into practice and keep them performing at their best.

The “Olympus Continuum” (www.olympuscontinuum.com) platform will empower HCPs at every stage of their career with innovative, premium education and specialized training experiences. The platform builds on the existing Olympus training program, which trains more than 25,000 HCPs annually over 1,400 courses.

Chief Medical Officer, Ross D. Segan, MD, MBA, FACS, said: “Healthcare professionals work in a variety of settings and have a multitude of needs–and their expectations for training courses have evolved well past traditional skills-based learning. Our new platform connects the continuum of care with the continuum of learning. A truly blended experience, Olympus Continuum maximizes digital self-guided pre-learning, direct in-person training, and post-learning collaboration to support healthcare professional across every stage of their career and to improve patient outcome.”

HCPs using the “Olympus Continuum” platform will enjoy the following benefits:

– Comprehensive platform programs covering basic to advanced levels: The Olympus global professional education strategy is to establish a continuum of blended learning that takes HCPs from basic to advanced, providing more educational opportunities/experiences and increasing accessibility through the utilization of technology. Hands-on courses will be provided in our 15 dedicated Olympus training labs, as well as hospitals and other labs all over the world.

– Beneficial for remote areas, including emerging countries: In some emerging countries and hard-to-reach areas, it has been difficult for HCPs to receive training or enroll in educational programs because of limited course offerings and large geographical distances. “Olympus Continuum” is a globalized and comprehensive platform of training and education experiences led by healthcare experts from around the world.

– Effective platform that fits well with current conditions created by the COVID-19 pandemic: There was growing demand from healthcare professionals for on-demand, digitally-enabled virtual training and this has increased further during the current COVID-19 pandemic. This new platform exactly meets this demand and provides an excellent combination of virtual and on-site training.

Learning opportunities include hands-on courses, online learning, lectures and workshops, peer-to-peer training, accredited continuing education and on-demand learning.* To learn more about
Olympus Continuum, visit www.olympuscontinuum.com

*Implementation will vary from region to region given market environments.

About Olympus Continuum

Olympus Continuum is a newly launched educational platform for healthcare professionals that will bring the benefits of digitally-enabled learning to remote regions, as well as those impacted by COVID-19. Basic and advanced training for healthcare professionals will be provided through Olympus training centers and hospitals all over the world.

About Olympus

Olympus is passionate about the solutions it creates for the medical, life sciences, and industrial equipment industries. Olympus’ Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments. For more information, visit https://www.olympus-global.com/.

For questions or additional information, please contact:
Europe, Middle East and Africa
Matthias Gengenbach
+49 4023773 5867
matthias.gengenbach@olympus-europa.com

Japan and Asia Pacific
Yuka Horimoto
+81-90-2490-1071
yuka_horimoto@ot.olympus.co.jp

New benchmark set to deliver optimal osteoporosis care throughout Asia Pacific

– Launch of first pan-Asia Pacific minimum clinical standards for the screening, diagnosis & management of osteoporosis –

The Asia Pacific Consortium on Osteoporosis (APCO) has today (Thursday, January 28, 2021) launched the first pan-Asia Pacific clinical practice standards for the screening, diagnosis, and management of osteoporosis, targeting a broad range of high-risk groups.

Published in Osteoporosis International today, ‘The APCO Framework’ comprises 16 minimum clinical standards set to serve as a benchmark for the provision of optimal osteoporosis care in the region.

Developed by APCO members representing key osteoporosis stakeholders, and multiple medical and surgical specialities, this set of clear, concise, relevant and pragmatic clinical standards aims to support national societies, guidelines development authorities, and health care policy makers with the development of new guidelines, and to encourage the revision of existing guidelines.

According to the Framework lead author, APCO Chairperson, and Director of the Osteoporosis and Bone Metabolism Unit at Singapore General Hospital, Dr Manju Chandran, Singapore, APCO employed a 5IQ analysis and the well-established Delphi Consensus process to analyse the 18 clinical practice guidelines currently available in the Asia Pacific region, to inform the development of The APCO Framework.

“Utilising a comprehensive, four-round Delphi consensus method enabled our APCO members who work in vastly different health care systems, to reach a remarkable level of consensus on a benchmark set of clinical standards for the provision of quality osteoporosis care for the Asia Pacific region.”

The APCO Framework offers clinicians structured, well-articulated, and readily accessible clinical practice guidelines that define:

  • Individuals to be identified for assessment;
  • Investigations required;
  • Relevant indications for treatment;
  • Appropriate selection of interventions to be made;
  • The guidance and information patients need for self-care;
  • Integration of healthcare systems for optimal provision of care; and
  • The need, and methods for monitoring and improving the quality of osteoporosis care.

“Implementation of The APCO Framework, or a similar set of standards of care informed by the Framework, is expected to significantly reduce the burden of osteoporosis not only in the Asia Pacific region, but also worldwide. We hope that the Framework can serve as a stimulus for harmonisation of guidelines in other regions that have similar socio-economic diversity and heterogeneity of health care resources,” Dr Chandran said.

Globally, the population aged 65 years or over increased from six per cent in 1990, to nine per cent in 2019.(1)
This proportion is projected to rise to 16 per cent by 2050,(1) meaning one in six people worldwide will be aged
65 years or over by 2050.(1) The number of people aged 60 years and over in the Asia-Pacific region – home to
more than a third of the world’s population aged 65 years and over, and to more elderly people than any other region(2) – is predicted to triple between 2010 and 2050, reaching a staggering 1.3 billion people.(3)

Osteoporotic fractures among Asia-Pacific populations are expected to increase exponentially, not only because of the region’s rapidly aging population, but also due to mounting urbanisation, and the subsequent increase in sedentary lifestyles.(4)

Despite the presence of generally safe and effective treatments for osteoporosis, as many as five in six patients presenting to their primary care physician (PCP), or to a hospital with a fragility fracture, will not be assessed for osteoporosis, nor appropriately managed to prevent further fracture.(5)

According to Medical Director of Osteoporosis Australia, and APCO Executive Committee member,
Professor Peter Ebeling AO, Australia, as many as half of those who have sustained a hip fracture, have already experienced a previous fracture at other skeletal sites.

“In fact, a prior fracture at any site is associated with a doubling of future fracture and mortality risk. The unfortunate ramifications of the gross under-diagnosis and under-treatment of osteoporosis is that a large number of people sustain further debilitating secondary fractures, which places a substantial, but importantly, preventable burden on already strained healthcare systems,” said Prof Ebeling.

A fragility fracture, which occurs every three seconds worldwide,(6) compromises quality of life and loss of independence.(6),(7) Concerningly, one-in-four patients who sustain a hip fracture die within a year, and less than half of those who survive, regain their previous level of function.(8),(9) In 2010, an estimated 158 million people aged
50 years and above were at high risk for osteoporotic fracture – a figure which is set to double by 2040.(10)

According to International Osteoporosis Foundation (IOF) CEO and APCO Executive Committee member,

Dr Philippe Halbout, Switzerland, these alarming statistics, coupled with the anticipated, exponential rise in osteoporotic fractures among Asia-Pacific populations, warrant a standardised set of minimum clinical standards for the region.

“Anecdotal evidence to date reveals significant inconsistencies in osteoporosis clinical practice guidelines in the Asia Pacific region, which vary widely in scope and recommendations. This was confirmed when we analysed the 18 guidelines.

“Implementation of the minimum clinical standards proposed by The APCO Framework, and reform of existing guidelines, will support clinical improvement initiatives, while also paving the way for a more holistic approach to osteoporosis care, and ultimately, greater consistency across all national and regional clinical practice guidelines in the region,” Dr Halbout said.

To download or access The APCO Framework, head to www.apcobonehealth.org/apco-framework

To learn more, visit www.apcobonehealth.org or follow APCO on LinkedIn: asia-pacific-consortium-on-osteoporosis

About APCO

The Asia Pacific Consortium on Osteoporosis (APCO) comprises osteoporosis experts from several countries and regions in the Asia Pacific, charged with developing tangible solutions to the substantive challenges involving osteoporosis management and fracture prevention in this most populated and fastest growing part of the world. APCO’s mission is to engage with relevant stakeholders, including healthcare providers, policy makers and the public, to help develop and implement country and region-specific programs for the prevention and treatment of osteoporosis, and its complication of fragility fractures, in the Asia Pacific.

About IOF

The International Osteoporosis Foundation (IOF) is the world’s largest non-governmental organisation dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF’s mission is to promote bone and musculoskeletal health as a worldwide priority.

The 5IQ analysis and Delphi consensus process

The 5IQ exercise assessed the extent of disparity when comparing the national guidelines currently available throughout the Asia Pacific region.

The Delphi technique (a structured communication technique using a systematic, interactive forecasting method reliant upon an expert panel) was employed to achieve APCO member consensus for the development of clinical standards of care.(11)

EXPERTS AVAILABLE FOR INTERVIEW

Dr Manju Chandran – APCO Executive Committee Chairperson, Senior Consultant, Department of Endocrinology, Director, Osteoporosis & Bone Metabolism Unit, Singapore General Hospital, SINGAPORE

Dr Philippe Halbout – Chief Executive Officer (CEO), International Osteoporosis Foundation (IOF), APCO Executive Committee member, SWITZERLAND

Prof. Peter Ebeling AO – Medical Director, Osteoporosis Australia & APCO Executive Committee member, AUSTRALIA

Dr Zhao Yanling – Obstetrician & Gynaecologist, Beijing United Family Hospital, & APCO Member, Beijing, CHINA

Prof. Atsushi Suzuki – Professor & Chair, Department of Endocrinology & Metabolism, Fujita Health University & APCO Member, JAPAN

Prof. Yoon-Sok Chung – Professor, Department of Endocrinology & Metabolism, Director, Ajou Institute on Aging, Ajou University Medical Center & APCO Member, SOUTH KOREA

Dr Hew Fen Lee – Consultant Endocrinologist, Puchong Medical Specialist Centre, Subang Jaya Medical Centre & APCO member, MALAYSIA

Dato’ Dr. Lee Joon-Kiong – Consultant Orthopaedic Surgeon, Beacon Hospital & APCO Member, MALAYSIA

Dr Nigel Gilchrist – Specialist Consultant Physician, Canterbury District Health Board & APCO ExecutiveCommittee Member, Christchurch, NEW ZEALAND

Mr Paul Mitchell – Adjunct Senior Lecturer, School of Medicine, University of Notre Dame Australia & APCO Executive Committee Member, Auckland, NEW ZEALAND

MEDIA CONTACTS & INTERVIEWS

Kirsten Bruce & Mel Kheradi, VIVA! Communications, Sydney, Australia
T +61 (0)401 717 566; +61 (0)421 551 257
E: kirstenbruce@vivacommunications.com.aumel@vivacommunications.com.au

DOWNLOAD THE APCO FRAMEWORK DIGITAL MEDIA KIT: www.apcoframeworkmediakit.org

References:
(1) United Nations – Department of Economic and Social Affairs, World Population Ageing 2019 Highlights. 2019.
(2) World Bank Group, Live Long and Prosper – Aging in East Asia and Pacific. 2016.
(3) United National Population Fund (UNFPA) Asia & the Pacific. Ageing. [cited Nov, 2020]; Available from: https://asiapacific.unfpa.org/en/node/15208.
(4) International Osteoporosis Foundation, The Asia-Pacific Regional Audit: Epidemiology, costs & burden of osteoporosis in 2013. 2013. p. 1-128.
(5) Royal Australian College of General Practitioners & Osteoporosis Australia, Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age. 2017.
(6) International Osteoporosis Foundation (IOF). Capture the fracture. [cited Jan, 2020]; Available from: https://www.capturethefracture.org/about.
(7) Madureira, M.M., R.M. Ciconelli, and R.M.R. Pereira, Quality of life measurements in patients with osteoporosis and fractures. Clinics (Sao Paulo, Brazil), 2012. 67(11): p. 1315-1320.
(8) National Osteoporosis Foundation, NOF’s Clinician’s Guide to Prevention and Treatment of Osteoporosis.
(9) Australian Institute of Health and Welfare. Musculoskeletal fact sheet. Osteoporosis. [cited Jan, 2020]; Available from: https://bit.ly/3qQOqbi
(10) Oden, A., et al., Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int, 2015. 26(9): p. 2243-8.
(11) Royal College of Obstetricians and Gynaecologists. The Delphi technique. 2005 [cited Jan, 2020]; Available from: https://bit.ly/39hWags

Broncus Holding Corporation Closed Series D Financing

HONG KONG, Jan 28, 2021 – (ACN Newswire) – Broncus Holding Corporation (“Broncus”), a global leader in diagnostic and therapeutic technology for lung diseases, announced today the closing of a Series D round of funding led by FountainVest Partners. Other investors include Exome Asset Management, Summer Capital, and Valliance Capital.

Broncus is dedicated to the development of diagnostic and therapeutic technology for lung diseases with focus on the diagnosis of lung cancer and the treatment of emphysema. Owning more than 200 patents, Broncus has built a comprehensive and robust pipeline of patented technologies using a disciplined approach. The Bronchoscopic Trans-Parenchymal Nodule Access (“BTPNA”) technology supporting the Archimedes System is able to access any part of the entire lung, reaching directly the lesions that are not connected to or adjacent to an airway. Leveraging its proprietary full-lung navigation technology, the company has developed an integrated interventional pulmonology platform encompassing navigation, diagnosis and treatment.

The funds raised in this round will be used for the commercialization and development of technology across lung cancer, emphysema and other important lung diseases. Efforts will include expanding commercial adoption and global clinical studies of the core products, and further development of next-generation radiofrequency technology to treat lung cancer with precision. Early investors in the company include Qiming Venture Capital, Lake Bleu Capital, DCP Capital, Ascendum Capital and Intuitive Surgical, an early pioneer and global technology leader in minimally invasive, robotic-assisted surgery.

Zhan Guowei, CEO of Broncus, said, “Our breakthrough navigation technology is enabling us to accelerate the development and commercialization of precise interventional technologies for diagnosis and treatment in order to improve options for patients with lung diseases and the physicians that care for them.”

Jason Li, Managing Director of FountainVest, said, “FountainVest Partners is excited to be supporting Broncus, one of the leading global players in the field of interventional diagnosis and therapy of lung diseases with proven capabilities to develop cutting edge innovative medical technologies. Leveraging FountainVest’s resource within the healthcare sector, we look forward to partnering with Broncus to explore further growth opportunities both domestically and globally.”

About Broncus Holding Corporation
Broncus is dedicated to the development of diagnostic and therapeutic technology for lung disease, a leading interventional pulmonology medical device player providing comprehensive lung solution offerings in China and globally. Founded in 2012, the company’s primary technology platforms focus on the diagnosis of lung cancer and the treatment of emphysema, and has developed an integrated interventional pulmonology platform encompassing navigation, diagnosis and treatment. The Archimedes System has been cleared by the FDA (U.S.), CE (Europe) and NMPA (China) and had broad patent protection globally. Under the unique R&D model, company combines international cutting-edge technologies with local R&D cost advantages to support a strong intellectual property portfolio and fast product iterations.

About FountainVest Partners
Founded in 2007, FountainVest Partners (“FountainVest”) is one of the most established independent private equity firms in Asia. FountainVest focuses on long-term oriented investments in industry leaders, partnering closely with management teams to drive growth and create value in diversified areas including in strategy, operations, finance, and industry consolidation. FountainVest has completed a number of successful landmark investments in Asia, Europe, and the United States. Sectors of focus include Consumer, Media & Technology, Healthcare, Industrials, and Financial and Business Services. FountainVest manages assets on behalf of world leading public pensions, sovereign wealth funds, and other institutional investors.

Media Contact:
Broncus
Shirley Deng
Email: shirley.deng@dnamedtech.com

Olympus to Acquire Quest Photonic Devices B.V. to Bolster Surgical Endoscopy Capabilities

Olympus Corporation (Olympus – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced that it has entered into an agreement to acquire Quest Photonic Devices B.V. (Quest – CEO: Richard Meester) for up to EUR50 million including milestone payments to strengthen its surgical endoscopy capabilities.

Headquartered in the Netherlands, Quest offers advanced fluorescence imaging systems (FIS) for the medical field, enabling more surgical endoscopy capabilities, compared to conventional imaging technologies.

Fluorescence imaging refers to special light imaging technologies that utilize the properties of fluorescent dyes directed to specific anatomical structures. By using targeted dyes, in combination with specific light wavelengths, tissues or lesions that are nearly invisible under normal white light become visible. Olympus’ existing laparoscopic imaging system, VISERA ELITE II, is already equipped with fluorescence imaging technology. VISERA ELITE II uses near-infrared light to identify blood vessels or lymph nodes under the surface tissues, aiming to assist surgeons in performing safer procedures with lower complication risks. The Quest technology acquired is intended to expand opportunities for Olympus in this field.

Making the Invisible Visible

Quest offers innovative technologies for multi-spectral imaging and imaging systems for medical applications, ranging from fluorescence imaging to photodynamic therapy. The acquisition strengthens Olympus’ position as a world leader in medical imaging solutions, and delivers innovative capabilities (including 3D and 4K imaging) to surgeons, to “make the invisible visible.”

Quest’s lead product line is the Quest Spectrum Fluorescence Imaging System, which enables fluorescence-guided surgery for open and minimally invasive procedures. Kanichi Matsumoto, global head of Surgical Endoscopy at Olympus, said: “We are delighted to incorporate Quest’s advanced FIS capabilities into our comprehensive medical imaging portfolio. The combination of the Quest Spectrum product line’s leading FIS technologies with Olympus’ existing laparoscopic imaging system VISERA ELITE II will enable Olympus to offer surgeons a wide range of high quality fluorescence imaging solutions.”

New Applications and Market Growth

The global market for FIS devices is expected to grow at a compounding annual rate of more than 12%, from around US$310 million in 2018 to over US$827 million in 2027*. Increasing demand for minimally invasive procedures and reconstructive surgery is helping to drive FIS growth worldwide. Furthermore, application of the FIS technology is expected to expand over the coming years, as additional fluorescent dyes are paired with targeted antibodies. Among other applications, molecular imaging will allow healthcare professionals to visualize cancerous lesions in vivo and perform cancer surgery in unprecedented ways, potentially lowering recurrence rates.

Quest also works with biotechnology companies that are developing next-generation molecular imaging dyes. These innovative dyes may enable Quest’s technology to advance diagnostic opportunities in fluorescence-guided cancer surgery.

*Source: Transparency Market Research; Near-Infrared Fluorescence Imaging System Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2019-2027.

About Quest

Quest Photonic Devices B.V. is a multispectral imaging leader and focuses on the medical markets of fluorescence image-guided surgery and cancer-targeted probes. Quest’s next generation Spectrum Florescence Imaging System has the ability to “see through tissue” with enhanced sensitivity, capable of accessing otherwise inaccessible information to aid the surgeon in improving clinical outcomes.

About Olympus’ Medical business

As a leading medical technology company, Olympus’ Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.

For questions or additional information, please contact:

Europe, Middle East and Africa
Matthias Gengenbach
+49 15142369420
matthias.gengenbach@olympus-europa.com

Japan and Asia Pacific
Yuka Horimoto
+81-90-2490-1071
yuka_horimoto@ot.olympus.co.jp

Citicode Ltd. Shareholders Approve Reverse Takeover of Homegrown Multi-Disciplinary Healthcare Specialist Livingstone Health Holdings Limited

Shareholders of Citicode Ltd., today approved the reverse takeover (“RTO”) of homegrown multi-disciplinary healthcare specialist Livingstone Health, marking the start of a new chapter of growth in Singapore and across the Asia Pacific region. At the extraordinary general meeting (“EGM”), shareholders of Citicode approved the RTO and the transfer of the Company’s shares from the SGX Mainboard to the Catalist Board and change of corporate identity to Livingstone Health Holdings Limited (“Livingstone Health Holdings”).

Livingstone Health Holdings has 15 medical doctors practising at 12 medical clinics and one medical spa located at various Singapore locations. It offers tertiary healthcare services such as aesthetics and wellness, anaesthesiology and pain management, internal medicine, orthopaedic surgery, and primary healthcare service such as family medicine, as well as other paramedical products and services including physiotherapy. It has formed a joint venture in Cambodia to provide aesthetics and wellness services, and also offers healthcare design consultancy services.

With a capital market platform, Livingstone Health Holdings plans to tap into the fast-growing healthcare sector by exploring other healthcare-related fields to complement its multi-disciplinary approach, and regional expansion via mergers and acquisitions, joint ventures and/or partnerships.

The successful EGM capped a combined new chapter for both Citicode and Livingstone Health. Citicode, under the leadership of its Executive Chairman and CEO Mr Teh Wing Kwan, had been seeking to transform the former Advance SCT Limited by evaluating growth strategies that led to a partnership with the medical group to offer integrated healthcare and engineering services. The partnership, in turn, led Mr Teh to consider the RTO, before negotiations commenced in late 2019.

Livingstone Health, previously known as Ardmore Medical Group Limited, had in 2019 withdrawn its proposal to list on the Catalist Board, citing developments related to its business operations at that time and changing market conditions. Under a new CEO, Dr Wilson Tay, it changed its name, increased specialisations and ventured into primary healthcare by acquiring a majority stake in homegrown family medicine service provider Phoenix Medical Group.

The reverse acquisition of Livingstone Health will be satisfied by a base and deferred consideration of S$47.0 million and up to S$25.0 million, respectively, of which up to S$2.0 million and up to S$1.5 million, respectively, will be in cash. New shares will be issued at S$0.20 per Consolidated Share.

The pro forma revenue and pro forma adjusted net profit after tax (“NPAT”) of Livingstone Health were S$14.3 million and S$3.2 million, respectively, for FY2019. Unaudited revenue and net profit for the six months ended 30 June 2020 (“6M2020”) were S$6.5 million and S$0.9 million, respectively.

Prior to the RTO, Citicode shares will first be consolidated on a 500-to-one basis, reducing its issued share base to approximately 82.6 million new Consolidated Shares from approximately 41.3 billion shares. After the RTO, Citicode share base will immediately be enlarged to approximately 315.9 million and up to 433.4 million by FY2022 upon issuance of base consideration shares and deferred consideration shares, respectively.

Voluntary trading suspension of Citicode shares is expected to start on 2 February 2021 to facilitate the expected completion of the RTO on 5 February 2021. Thereupon, the vendors comprising senior management and key doctors of Livingstone Health Holdings will be the new controlling shareholders of the Company.

Dr Wilson Tay will serve as Executive Director and CEO of Livingstone Health Holdings, while Mr Teh Wing Kwan, Citicode’s current Executive Chairman and CEO, will be redesignated as Non-Executive and Non-independent Chairman and will remain as a substantial shareholder. The board of directors of the Livingstone Health Holdings will also include the existing Independent and Non-Executive Directors Mr Fong Heng Boo and Mr Chan Yu Meng and the newly appointed Mr Lim Jun Xiong Steven. The continued appointments of the existing board further underscore their confidence in the RTO.

Dr Tay said: “We thank Citicode’s shareholders for supporting this transformation. The Livingstone Health team is excited by the growth opportunities. We are committed to delivering shareholder value through expansion in Singapore and the region, leveraging on our combination of primary and tertiary healthcare on a single platform which emphasises medical outcome and good governance.”

Mr Teh Wing Kwan said: “The successful EGM marks the beginning of a new chapter of growth as a fast-growing healthcare services company poised to capture new opportunities at home and abroad with its brand of integrated healthcare. I thank shareholders of Citicode for their support of this corporate transformation.”

SAC Capital Private Limited is the Financial Adviser in respect of the RTO and Sponsor of the Company upon the transfer to the Catalist Board.

Trading of the Company’s shares, post-consolidation, is expected to resume trading on 8 February 2021, 9:00 am.

About Livingstone Health
Livingstone Health Ltd. (“Livingstone Health” and together with its subsidiaries, the “Group”) is a Singapore-based multidisciplinary healthcare group whose core competencies include Aesthetics & Wellness, Anaesthesiology & Pain Management, Family Medicine, Internal Medicine and Orthopaedic Surgery.

The name “Livingstone” is inspired by the succulent plant Lithops, also known as “living stones”. They symbolise the Group’s resilience, growth and determination to be recognised as a trusted integrated healthcare provider for patients, as well as a centre of excellence of growth opportunities for medical professionals.

The Group has 15 medical doctors practising at 12 medical clinics and one medical spa located at convenient and accessible locations throughout Singapore. In addition, the Group has also ventured into other paramedical products and services, such as physiotherapy. It has a joint venture to provide aesthetics and wellness services in Cambodia and also offers healthcare design consultancy services. For more information, please visit: www.livingstonehealth.com.sg

About Citicode Ltd. (SGX:5FH)
Listed on the Mainboard of the Singapore Exchange since 2004, Citicode Ltd. is the result of the business transformation and corporate rebranding of the former Advance SCT Limited in 2018. Citicode reflects the reimagined corporate identity composed by the new Board and management team.

Citicode has diversified into new business segments including M&E for mission critical functions, as well as civil and structural engineering for land transport infrastructure, with a view to form an ecosystem to support smart city applications while evaluating other strategic application plans.

Media & Investor Contact Information
WeR1 Consultants Pte Ltd
1 Raffles Place
#02-01 One Raffles Place Mall Suite 332
Singapore 048616
Isaac Tang, livingstone@wer1.net (M: +65 9748 0688)

Heathrow Covid Chaos British Tech Co Has Solution

BRITISH TECH COMPANY HAS
GLOBAL COVID & VACCINATION
SECURE PASSPORT SOLUTION
FIRM WARNED OF SERIOUS RISKS TO AIR TRAVEL IN DECEMBER
FROM FAKE COVID 19 TEST & VACCINE CERTIFICATES
HEALTH PASSPORTS WITH UNSECURE QR & BAR CODE TECHNOLOGY
https://v-healthpassport.co.uk

British tech company VST Enterprises (VSTE) warned airlines and the travel industry in December of last year of ‘Covid related security threats’ prior to the chaotic scenes that unfolded at Heathrow airport (Monday 18th Jan).

Tech boss and CEO Louis-James Davis warned of the very real and serious threats facing airlines, airports and passengers from fake Covid 19 test certificates, vaccination record cards, social distancing breaches and the use of health passports with ‘un safe’ QR and bar code technology. He also warned of the serious implications of potential data breaches using ‘unsecure’ code scanning technology in health passports.

Passengers arriving into the UK this week (Monday) were faced with unprecedented scenes at Heathrow airport with long delays, social distancing rules breached, altercations between passengers and border officials, GBP500 on the spot fines and passengers being refused entry to flights for holding invalid Covid 19 certificates. The chaos came as the British Government put in place tough new measures for entry into the UK in a bid to get a grip of the pandemic and prevent the further spread of infection. Passengers were required to provide verifiable proof of their Covid 19 negative test result.

VSTE developed and launched the worlds first secure digital health passport called V-Health Passport(TM) in April (2020) both for passengers and airlines which authenticates a persons health status including Covid test status and their vaccination records all within a secure digital passport. The V-Health Passport(TM) ‘cross border’ technology can be used across all air, land and sea transport infrastructure. The V-Health Passport(TM) has over 200 clinics across the UK where a person can book a Covid test – including a PCR based test – and be recognised as ‘FIT TO FLY’ by all International airlines. VSTE believes its solution can solve the global airline and travel issue.

V-Health Passport(TM) will shortly start its roll out program of secure health passport across number of airlines and airports globally. In the UK it has already started this programme and is available through its healthcare testing partners Salutaris People www.salutarispeople.com and Akea Life at www.akealife.co.uk both at Newcastle and Liverpool John Lennon airports.

Both healthcare partners also offer full airline travel Covid testing at their own clinics with PCR based testing for airline travel with a V-Health Passport(TM). They also supply ‘home test kits’ which are supervised over Zoom calls.

It is the first company in the world to have a fully functioning and secure LIVE health passport that carries a persons Covid test status and vaccination record in one secure app. Most importantly the technology is GDPR compliant and was built on a privacy framework of ‘Self Sovereign Identity’ where the person – or airline passenger – can choose what information they want to share, when they want to share it and with who. Privacy by design is at the forefront of the V-Health Passport(TM) framework unlike other health passport technologies.

V-Health Passport(TM) is a test and vaccine agnostic platform working with all Covid 19 protocols from PCR to rapid antigen and antibody tests which can also authenticate a persons vaccine immunisation record. V-Health Passport(TM) is also the most secure passport technology in the world unlike bar codes and QR codes which are subject to a process called ‘Attagging’ where a QR code can be cloned and faked. Using the VCode(R) cyber coding, it works on a ‘closed loop’ system with ‘end-to-end’ encryption and has over 2.2 Quintillion variations of codes that are subject to many scanning permissions making it impossible to hack the front or back end.

V-Health Passport(TM) is 10 seconds faster than any code scanner and can also be scanned within and outside of the safe social distancing of 2 metres, whereas bar codes and QR codes have to be scanned in close proximity of inches. In other circumstances it can also be scanned upto 100 metres away, allowing for easier crowd and queue ingress and egress.

In addition to the security flaws and close proximity of QR code scanning, another downfall of using QR Code for this type of passport solution is that a user may have to carry hundreds of different QR codes for the same identity use case. Companies who wish to add any form of extra security to the QR code would also have to offer their own app to scan a QR code which may lead to a consumer having to carry 100’s of apps or codes due to the QR codes open source nature (not being generated from a central source).

Commenting on the chaos around the events at Heathrow, VSTE CEO Louis-James Davis said;
“The scenes at Heathrow could have been easily avoided by using a secure system such as V-Health Passport(TM). Both airports and the airlines need to move to a secure digital platform technology to ensure the security and faster processing of passengers to verify their Covid status and vaccination records. We have that technology now and it is available for airline passengers and the airlines to download and use today. By using the V-Health Passport(TM) technology a passengers valid Covid 19 test certificate could have been scanned further than the 2 metre safe social distancing protocols and upto 100 metres away. This would have allowed for a smooth ingress of passengers coming through border control into the UK verified against their identity. This would have also helped the passengers to maintain safe social distancing and a much quicker processing through border control thus avoiding the social breaches which occurred.

The V-Health Passport(TM) would not only provide border officials and airports with authentication of an airline passengers Covid 19 test status – with both a digital and printed PCR test certificate – but also their vaccination records. The technology also verifies a persons genuine identity against their existing Government ID adding another layer of security. There has been a phenomenal rise in the sale of ‘Fake Covid’ certificates, with both Russia and the Middle East seeing the greatest activity and posing a serious threat to global aviation security.

Using any open-source technology such as RFID, bar code or QR code with any form of health passport or vaccine card/certificate leads it wide open to being hacked or cloned with a person effectively making themselves ‘permanently Covid negative’ and ‘permanently vaccinated’ and allowing them to travel freely. By moving towards a secure ‘one for all’ technology based solution that passengers can use with their phones, will not only protect the data of passengers but also the safety of their health. It will ensure that a passenger who is travelling has a valid Covid test result or vaccine immunisation record and ensuring other fellow passengers are safe.”

The V-Health Passport(TM) technology has a complete audit trail of a persons Covid testing, their vaccination records and the clinics where those tests or vaccinations have been conducted. This information is also protected under the ‘Self Sovereign Identity’ data framework allowing only the passenger to view this information, with officials only able to see a current and valid Covid 19 test or vaccine status in the GDPR display of the app.

With the alarming increase and black market trade in fake Covid 19 test certificates and also vaccination cards and certificates this also puts a very real threat and risk to passenger safety. It poses a threat to airlines and international borders with the potential for a passenger carrying a fake Covid test certificate or vaccination card – who may be asymptomatic – to board an aircraft and infect other passengers. This poses a very real threat to the aviation sector and to Governments around the world as they try to arrest the rate of infection.

It is well documented that bar codes and QR codes can be hacked so any airline who considers using a health passport for Covid 19 testing and vaccination using this method of authentication risks a serious potential breach of its passenger data. In 2018 British Airways was fined a record GBP20M for a data breach on 400,000 of its customers which affected their personal and credit card data. It now faces one of the biggest ever group privacy claims in UK legal history as reported in the Financial Times. It comes at a time when security over the use of bar codes and QR codes in airline travel has come under intense scrutiny following the cyber attack last year on the former Australian Prime Minister Tony Abbot. The former PM had his Qantas airline boarding pass hacked. Details including his passport, mobile phone and messages between Qantas staff about him were intercepted.

VSTE CEO Louis-James Davis added;
“We are the first technology company in the world to have developed a secure, multipurpose, cross corporate & cross government digital health passport that does not rely on using bar codes or QR codes as its authentication technology. Both bar codes and QR codes have huge potential security implications as they can be cloned and hacked with the latter being subject to a process called ‘Attagging’. Therefore any suggestion of using this type of technology in a health passport for air travel has very real security risks. Not only is a citizen’s personal information at risk, but their Covid test status, vaccination records and also their credit card information. All of this can lead to the very real potential of a massive data breach and a persons personal information and data hacked and stolen. This is of particular concern when using a bar code or QR code technology designed for use to authenticate a persons Covid 19 testing and/or vaccinations records.”

Unlike other health passports, V-Health Passport(TM) has been designed with a citizens privacy front and centre. The technology does not track your live location and provides all data in a secure GDPR compliant framework giving citizens a unique ‘self sovereign identity’ style technology putting them in control of who, when and how they share their data.

Louis-James Davis went on to state that both bar codes and QR codes – which represent first and second generation technology – are unsecure and vulnerable to hacking.

“QR codes were originally developed as a scanning technology for close proximity car parts tracking, a world away from identity and banking use cases and now digital health passports. It was then used to skip the input of websites in marketing and promotional purposes. They were never designed with security or privacy in mind… they are simply not fit for purpose and should not be used at all in any form for delivery of sensitive information, travel or event tickets or health passport.”

QR codes can be subject to a process called ‘Attagging’ or ‘cloning.’ The process of ‘Attagging’ is where a ‘genuine QR code’ is replaced by a ‘cloned QR code’ which then redirects the person scanning that code to a similar website where personal data can be intercepted and breached. The problem is that serious that in India alone there are over 1BILLION fraudulent financial transactions each day using QR codes. As the scanning user journey is the same, it is only tech savvy individuals that may notice the domain name has changed.

QR codes can be cloned and redirected to other information points or websites. Often criminals and hackers will exploit this by putting a fake QR code over a genuine QR code. So a QR code for example on scanning would link to the genuine website www.similardomain.com but a fake QR code can be made up printed off and placed over the genuine code to redirect to www.similar-domain.com at this point the member of the public is tricked into entering their personal information, private data and financial information. The rogue website looks and feels exactly like the genuine one and is made to mirror it precisely.

VCode(R) which is the ultra secure digital code which powers the V-Health Passport(TM) cannot be cloned. Even if it was printed off, or a photograph was taken and placed over a VCode(R) or V-Health Passport(TM) it simply won’t scan as it works on a call and response system of information between the code and web platform to verify location of the code, user ID and time and date and much more.

V-Health Passport(TM) is making a significant contribution to the safety, mobility and return to work of the UK economy, helping businesses and employers return their staff to offices, factories and warehouses.

VSTE is working with the UK Government and a number of other Foreign Governments around the world to use its technology. The company is active in multiple industries and sectors including the maritime and aviation industries, construction and major infrastructure projects, as well as major national and international sporting events. V-Health Passport(TM) is also being used by a number of private Covid testing clinics, manufacturers and healthcare practices.

V-Health Passport(TM) is available on the Apple App Store and Google Play by searching for ‘VPassport’ and downloading to your device.

For more information on VCode(R) and VPlatform(R) technology please visit
https://www.vstenterprises.com

For more information on V-HEALTH PASSPORT(TM).
https://v-healthpassport.co.uk

For all media enquiries
Please contact Gerard Franklin – Head Of Communications & External Relations
M: 07885 388398 e: gerard@vstenterprises.com
VST Enterprises Ltd | The Lexicon | Mount Street | Manchester | M2 5NT

NOTES TO EDITORS
About the V-Health Passport(TM)
Search ‘VPassport’
Apple App Store & Google Play
www.v-healthpassport.co.uk

Available on the Apple App Store and Goole Play by searching for ‘VPassport’ and downloading to your device.

– V-Health Passport(TM) can be scanned at a safe social distance of 1-2 metres and upto 100 metres away. QR code and Barcode technology has to be scanned inches away and as such breaches social distancing protocols.
– The V-Health Passport(TM) can authenticate a persons genuine Covid 19 test certificate – held in the secure health passport app and a printable version. The ultra-secure platform can now also hold vaccination records of all the major vaccination manufacturers which will be crucial in a person validating they have been vaccinated, the vaccine type, batch, dosage and date.
– V-Health Passport(TM) uses a persons official Government ID such as drivers licence, passport and cross matches against databases. It is then paired against a facial recognition ‘Live Likeness’ test to verify the persons genuine status.
– V-Health Passport(TM) is a test agnostic platform meaning it works with all Covid testing protocols from PCR based tests to rapid antigen and antibody. It has over 200 clinics across the UK on its app for passengers to book a Covid 19 test including a PCR based test approved for International airline travel.
– V-Health Passport(TM) can be scanned in a 170 degree arc, whilst a person is moving and thus ensures smooth ingress and egress,
– V-Health Passport(TM) It uses the worlds most secure cyber coding technology which works from a close loop system with end to end encryption and has over 2.2 Quintillion combination codes making it impossible to hack the front of back end of its system.
– V-Health Passport(TM) is a GDPR compliant technology built around self sovereign identity, allowing the airline passenger or member of the public to choose what data they want to share, with whom and when.
– V-Health Passport(TM) is available now and can be downloaded from the Apple App Store or Google Play by searching for ‘VPassport’ or by visiting www.v-healthpassport.co.uk.
– V-Health Passport(TM) also has its own unique contact tracing capability ‘True Contact(TM)’ built within the technology designed for travel, sports stadiums, venues, factories, offices and construction sites.
– V-Health Passport(TM) is the only health wallet and cross border platform in the world that is multi-functional and GDPR compliant. It allows acts like ‘self sovereign identity’, meaning a citizens personal data is protected and they choose what they want to share and with whom they want to interact or authorise.

SOURCE: VST Enterprises Ltd

KIEYYUEL’s disposable nitrile gloves – No.1 in the medical industry

GUANGDONG, CHINA, Dec 24, 2020 – (ACN Newswire) – The 2020 China (Dongguan) International Forum & Exhibition on Epidemic Prevention and Health Industry Development was held at the Dongguan Guangdong Modern International Exhibition Center, sponsored by Dongguan Municipal People’s Government, with guidance from the China Chamber of Commerce of Medicines and Health Products Importers and Exporters.

The scope of this medical epidemic prevention exhibition included mask equipment and raw materials, mask products and epidemic supplies, sterilizing and disinfecting equipment, big health products and comprehensive services, and more. Invited by Chang’an Town Economic Development Bureau, Shenpu Technology, with its four business representatives presented a comprehensive collection that became a highlight of the exhibition once again for its excellent product quality, abundant variety and comprehensive certification.

Shenpu Technology’s main brand KIEYYUEL can be divided into more than ten series: disposable masks, N95 face masks, FFP2 respirator masks, FFP3 filter masks, disposable nitrile, latex and vinyl gloves, protection suits, operation gowns, goggles, face shield, disposable non-woven foot cap, body bags, infrared thermometers, and more, which have passed the relevant inspections and authentication for NMPA, CE, FDA, ISO9001, ISO13485, SGS, ITS, and TUV, and can be used in the fields of hospital and medical, chemical and laboratory, hairdressing and beauty, food processing, machine maintenance, electronic components, cleaning and maintenance operations, pet cleaning, and many more.

Shenpu Technology is a modern enterprise of product processing, developing, producing and sale, which has 100 thousand level clean workshops, 10 thousand level microbiology laboratory, bacterial filtration efficiency tester, partial filtration efficiency tester and other detecting instruments. With a double guarantee of strength and quality, Shenpu Technology entered the National Business White List, Guangdong’s leading brand in the medical device industry, a AAA grade model business unit.

Since its establishment, Shenpu Technology has always been taking corporate social responsibility as its responsibility and regards building a harmonious community as its responsibility and goal. At present, KIEYYUEL series products are exported to UK, Germany, Chile, Spain, the United States, Japan, Malaysia, India, and more than 40 countries with 10 International logistics stations in total, showing KIEYYUEL’s will to fight the pandemic and overcome the difficulties together with its global partners.

In this exhibition, KIEYYUEL series products were highly regarded by the domestic and foreign businessmen, who reaffirmed their orders with Shenpu Technology gathering the purchasing intention of many clients on site. Shenpu Technology will galvanize the faith and seize the opportunity, creating an international high-tech enterprise through modern management policy, technology innovation and efficient execution.

Media contact:

Guangdong Shenpu Technology Co., Ltd./KIEYYUEL

Jasmine, E: doris@kieyyuel.com

T: +852 57663170, www.kieyyuel.com

Suntrap Life Technologies Discovers Natural anti-COVID-19 Compound

‘LeSoleil’, a naturally active compound, was discovered as a therapeutic candidate for use against COVID-19. As the new coronavirus began to spread globally, Suntrap Life Technologies Ltd established a special research team. The project, “Research on Anti-New Coronavirus (COVID-19) Prevention Products”, was launched in an emergency situation. Working from the naturally active compounds screening and discovery platform developed by the International Drug Discovery Network Unites (IDDNU)*, the Suntrap research team conducted high throughput virtual screening of all naturally active compounds in the library, aiming to isolate compounds with a potent antiviral activity while ensuring safety.

Consequently, ‘LeSoleil’, a potential therapeutic treatment was discovered. After further evaluation of its antiviral activity and safety, a sensitivity experiment with COVID-19 and ‘LeSoleil’ was scheduled in conjunction with Guangdong Provincial Center for Disease Control and Prevention and Guangdong Provincial Institute of Public Health. With core R&D progressing smoothly, the effective prevention, and treatment, of COVID-19 were coming into view.

The sensitivity experiment was started in August, lasting one month. The results indicated ‘LeSoleil’ has a potent in vitro inhibitory effect on COVID-19, with great potential to become a drug candidate. The experimental details showed that the TC50 (Half Toxicity Concentration) of ‘LeSoleil’ is 71.16 nM, within which the highest inhibitory rate for COVID-19 reached 99.41%. In addition, ‘LeSoleil’ retained a high inhibitory effect against COVID-19 even at low concentration, which has been particularly prominent in several verification experiments. The images show the viability of cells at a concentration of 114.8 nM, with an unexpected inhibition rate up to 63.06%.

Furthermore, the in vivo experiment showed LD50 of ‘LeSoleil’ is above 2000 mg/kg. As a naturally occurring compound, the plant-derived ‘LeSoleil’ has the advantages of low toxicity, good tolerance, and high accessibility, which provide a guarantee for the rapid development of multi-dose protective and therapeutic drug products.

The research team completed the formulation of “ShengPu No.1” and “ShengPu No.2”, which provide protection against COVID-19 in the nasal cavity and the oral cavity, respectively, in a spray dosage form. In these formulations, the antiviral effects of ‘LeSoleil’ remain the best while ensuring safety. At the same time, drugs and clinically therapeutic formulations for the treatment of COVID-19 are being further explored.

Suntrap researchers hope to develop effective drugs for the prevention and treatment of the broad-spectrum coronavirus as soon as possible.

*http://suntrap-centre.com/iddnuhttp://www.suntrap.com

Contact:
Suntrap Life Technologies Ltd.
Zoe Zhou, Media Supervisor
E: 2113@suntrap.com
T: +86 18825197167

The copyright in this article belongs to Suntrap Life Technologies Ltd.
22 Longrong Road, Hualong Town, Panyu District, Guangzhou, China.
Any reproduction must cite Suntrap Life Technologies Ltd, http://www.suntrap.com as the source.

UK Tech Firm Launches Covid & Vaccination Passport

– British Tech Firm Launches Worlds First 5 In 1 Secure Health Passport Wallet
– Free ‘Self Sovereign ESQ ID’, Secure Cross Border Platform is being used for Air Travel, Return to Work, Stay at School, Hospitality & Will Soon See Sports Fans Return to Capacity Stadiums
– Tech Innovator Warns Of ‘Un Secure’
– ‘QR’ Code & Data Breaches in Health Passports
– Following Former Australian Prime Minister Airline Boarding Card Hack

British technology company VST Enterprises has today confirmed it has developed the worlds first secure 5 In 1 digital health passport and wallet. V-Health Passport(TM) is a crucial ‘safe technology enabler’ in reviving global economies, home lives and helping Governments, business and industry to start returning to work and normality.

The cross border, cross corporation V-Health Passport(TM) can be used by international Governments, consumers and companies to authenticate a persons true identity, their Covid test results and vaccinations. This ‘enabler’ allows them to prove their test and/or vaccination status. Uniquely the V-Health Passport(TM) has its own contact tracing capability using anonymised data, whilst also protecting citizens data and privacy with a concept in the vein of ‘self sovereign identity’.

Manchester headquartered VSTE have innovated the V-Health Passport(TM) to be the most secure digital health passport and wallet in the world, but at the same time multi functional and future proof to deal with all future pandemics;

The V-Health Passport(TM) has 5 key ‘enabling’ features to its technology;

– Powered by the worlds most secure cyber security coding technology VCode(R) it is the worlds most secure ‘next generation’ code scanning technology using a closed loop system with end to end encryption and 2.2 Quintillion collision free codes (A VCode(R) can only exist once due to being encoded from a centralised system).
– V-Health Passport(TM) is a test agnostic system so it can record results from all global Covid testing manufacturers and protocols from PCR to rapid antigen and antibody testing.
– V-Health Passport(TM) also has its own unique contact tracing capability ‘True Contact(TM)’ built within the technology designed for travel, sports stadiums, venues, factories, offices and construction sites.
– The ultra-secure platform can now also hold vaccination records of all the major vaccination manufacturers which will be crucial in a person validating they have been vaccinated, the vaccine type, batch, dosage and date.
– Uniquely V-Health Passport(TM) is the only health wallet and cross border platform in the world that is multi-functional and GDPR compliant. It allows acts like ‘self sovereign identity’, meaning a citizens personal data is protected and they choose what they want to share and with whom they want to interact or authorise.

But at the same time tech boss Louis-James Davis – CEO of VST Enterprises warned of the potential dangers and reliance on using QR code scanning technology within any form of health passport for airline travel or entry into a venue or workplace which could lead to potential security breaches of personal data and information.

It follows the hack and breach earlier this year of the former Australian Prime Minister Tony Abbot whose Quantas airline boarding card was hacked and details revealed including his passport number, mobile phone number and Qantas airline messages referring to the former PM.

Louis-James Davis went on to state that both bar codes and QR codes – which represent first and second generation technology – are unsecure and vulnerable to hacking.

“QR codes were originally developed as a scanning technology for close proximity car parts tracking, a world away from Identity and banking use cases and now digital health passports. It was then used to skip the input of websites in marketing and promotional purposes. They were simply never designed with security or privacy in mind… they are simply not fit for purpose and should not be used at all in any form for delivery of sensitive information, travel or event tickets or health passport. QR codes can be subject to a process called ‘Attagging or ‘cloning.’ Louis-James Davis said.

Davis also warned that the public will not tolerate breaches of their personal data and information along with their already existing and heightened concerns over privacy during the pandemic. He continued;

“Attagging is where a ‘genuine QR code’ is replaced by a ‘cloned QR code’ which then redirects the person scanning that code to a similar website where personal data can be intercepted and breached. The problem is that serious that in India alone there are over 1 BILLION fraudulent financial transactions each day using QR codes. As the scanning user journey is the same, it is only tech savvy individuals that may notice the domain name has changed.”

As reported by a recent Forbes Magazine investigation, it is predicted that over 11 Million households in the US alone will scan a QR code this year and the majority of them, some 71% of people who have interacted with a QR code will not know if it is the start of a malicious hack. It is envisaged that over 5.3 Billion QR codes will be redeemed this year making it one of the fastest growing tech scanning interactions and also posing one of the greatest cyber threats.

QR codes can be cloned and redirected to other information points or websites. Often criminals and hackers will exploit this by putting a fake QR code over a genuine QR code. So a QR code for example on scanning would link to the genuine website www.similardomain.com but a fake QR code can be made up printed off and placed over the genuine code to redirect to www.similar-domain.com at this point the member of the public is tricked into entering their personal information, private data and financial information. The rogue website looks and feels exactly like the genuine one and is made to mirror it precisely.

VCode(R) which is the ultra secure digital code which powers the V-Health Passport(TM) cannot be cloned. Even if it was printed off, or a photograph was taken and placed over a VCode(R) or V-Health Passport(TM) it simply wont scan as it works on a call and response system of information between the code and web platform to verify location of the code, user ID and time and date and much more.”

Louis-James Davis said; “We developed and built the V-Health Passport and health wallet to be the most secure technology on the planet that you could use as a health passport where you could combine your test status, vaccination record, boarding pass, airline ticket, music or sports ticket all in one app.

With V-Health Passport(TM) we wanted to provide functionality and greater mobility to allow citizens to return to work, be fit to fly or return to the sports stadiums. But at the heart of the technology was the ability to protect and respect data privacy of the individual.

The lack of engagement and interaction by the public with Government track and trace app/s over the pandemic was over privacy, security of data and the tracking of a persons live location. This is why we have built a unique system in the vein of ‘Self Sovereign ID’ with the ethics of privacy & security by design. The V-Health Passport(TM) puts the citizen in control in a way which they share information with who, when and where.”

By having a technology health wallet which confirms your Covid test status and your vaccination record/s it then becomes a ‘safe technology enabler’ to assist Governments, companies, consumers and organisations to resume greater mobility and returning life back to normality. But critically this technology will help revive and restore economic prosperity.

V-Health Passport(TM) will help employers safely return their employees back to their offices, factories and warehouses. It will facilitate airlines to allow their passengers to be fit to fly and avoid the need for quarantine restrictions. At the same time it will ensure their airline ticket or boarding pass is secure and won’t be hacked.

V-Health Passport(TM) will allow sports fans to return to the stadiums at capacity and not at the current socially distanced crowd protocols of 2000 fans. It will help get the hospitality sector back on its feet welcoming customers back. Because of the way V-Health Passport(TM) is designed – based on interaction and incentive – the hospitality sector can engage with with unique offerings and discounts to its customers.

V-Health Passport(TM) will help the Live music and entertainment sectors resume their concerts and performances in arenas, stadiums and theatres. They will be safe in the knowledge that fans have either been tested or vaccinated and can authenticate their status.

A citizen will be able to share their health pass and confirm their Covid test status, or present their vaccination record. They will also be able to show their credit score, work permit or visa, scan their travel or event pass. At the heart of each interaction they will have peace of mind that their data and information is highly secure and ultimately, they control who sees what, who scans what, where and when.

For more information on V-HEALTH PASSPORT(TM).
https://v-healthpassport.co.uk

For more information on VCode(R) and VPlatform(R) technology please visit
https://www.vstenterprises.com

For all media enquiries
Please contact Gerard Franklin – Head Of Communications & External Relations
M: 07885 388398 e: gerard@vstenterprises.com
VST Enterprises Ltd | The Lexicon | Mount Street | Manchester | M2 5NT

SOURCE: VST Enterprises Ltd & VHealth Passport

TAITRA Launches 2020 Online Medical Show

Taiwan External Trade Development Council (TAITRA), the operator of the nation’s largest B2B portal Taiwantrade.com, has launched the 2020 Online Medical Show.

The dedicated online showcase houses 700 medical products from 28 leading medical suppliers. A creation of such online exhibition, TAITRA believes, not only will make a contribution to the global medical and healthcare industries during the pandemic, but will help Taiwan’s suppliers gain enormous publicity.

In meeting global demands for pandemic prevention, TAITRA also created the Anti-epidemic and Stay-at-home Economy online showcases, which cover 20,000 products from 15 industries.

Taiwantrade.com, the largest B2B portal in Taiwan with an annual traffic of 32.5 million visitors, is sponsored by the Bureau of Foreign Trade and organized by TAITRA. In February, inquiries from worldwide buyers on the website grew 170% compared to the previous month.

According to TAITRA Digital Commerce Department Director Chen Ling-chun, the pandemic led to a drastic increase in the number of inquiries for healthcare products on the website. Inquires for stay-at-home products also rose sharply due to the deployment of lockdowns and quarantines worldwide. Catering to the global demand for stay-at-home supplies, many companies had begun to offer new lines of home entertainment and instant food products.

— 2020 Online Medical Show : https://medical.taiwantrade.com/mp/online-show
> Featuring 28 leading medical suppliers and 700 medical products.

— Anti-epidemic Economy showcase : https://anti-epidemic.taiwantrade.com
> Over 10,000 products from 7 major industries; medical consumables, diagnoses and monitoring, hospital & nursing equipment, surgeries and clinical treatment, pharmaceutical and health supplements, wound care, and first aid supplies & health supplies.

— Stay-at-home Economy : https://stayathome.taiwantrade.com
> Over 10,000 products from 8 major industries – audio video equipment, video games, video conferencing equipment, fitness & gym equipment, kitchen appliances, instant foods, computer peripherals & cellphones/tablets, and tabletop games & DIY handicraft materials.

About TAITRA
Founded in 1970 to help promote foreign trade, the Taiwan External Trade Development Council (TAITRA) is the foremost non-profit trade promotion organization in Taiwan. Jointly sponsored by the government, industry associations, and several commercial organizations, TAITRA assists Taiwan businesses and manufacturers with reinforcing their international competitiveness and in coping with the challenges they face in foreign markets.

Contact TAITRA
Ling-Chun Chen / lingchun@taitra.org.tw / www.taitra.org.tw
The Taiwan External Trade Development Council (TAITRA)